Sign inJoin waitlistJoin the waitlist

George Duvall

Physician · Mother Frances Hospital Regional Health Care Center

Credentials: · ·

History

Mother Frances Hospital Regional Health Care Center
Present

Gastroenterology
University of Texas Medical Branch Hospitals
1993–1996
Baylor College of Medicine
1990–1993
Baylor College of Medicine
1986–1990

Research

Streptococcus pneumoniae colonization, bacteremia, and immune response among persons with human immunodeficiency virus infection
The Journal of Infectious Diseases · 1993 · 101 citations
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials
The Lancet. Gastroenterology & hepatology · 2022 · 84 citations
Phase 2: a dose-escalation study of OncoGel (ReGel/paclitaxel), a controlled-release formulation of paclitaxel, as adjunctive local therapy to external-beam radiation in patients…
Anti-Cancer Drugs · 2009 · First of 5 authors · 57 citations

Bruce Sands
3 papers
David Rubin
2 papers
Corey Siegel
1 paper
DM
Daniel Mishkin
1 paper
DW
David Walden
1 paper
DN
Deanna Nguyen
1 paper
Dermot McGovern
1 paper
Edward Janoff
1 paper
HK
Houssam Al Kharrat
1 paper
John DeWitt
1 paper
JD
John Douglas
1 paper
MY
Mark Yen
1 paper

Clinical trials

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
Site PI · Recruiting · Phase 2
Eli Lilly and Company
2026–2031
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
Site PI · Recruiting · Phase 2
Eli Lilly and Company
2025–2029
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2028
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2028